Trial Profile
Phase III trial of subcutaneous ofatumumab in patients with neuromyelitis optica
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 27 Aug 2023
Price :
$35
*
At a glance
- Drugs Ofatumumab (Primary)
- Indications Neuromyelitis optica
- Focus Registrational; Therapeutic Use
- Sponsors GSK
- 16 May 2015 Status changed from planning to recruiting, based on GlaxoSmithKline pipeline.
- 11 Nov 2014 New trial record